Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CureVac N.V (CVAC) Receivables: 2019-2025

Historic Receivables for CureVac N.V (CVAC) over the last 4 years, with Jun 2025 value amounting to $462,971.

  • CureVac N.V's Receivables fell 98.21% to $462,971 in Q2 2025 from the same period last year, while for Jun 2025 it was $29.0 million, marking a year-over-year decrease of 59.96%. This contributed to the annual value of $18.0 million for FY2024, which is 11.12% up from last year.
  • Latest data reveals that CureVac N.V reported Receivables of $462,971 as of Q2 2025, which was down 88.89% from $4.2 million recorded in Q1 2025.
  • In the past 5 years, CureVac N.V's Receivables ranged from a high of $31.5 million in Q1 2022 and a low of $462,971 during Q2 2025.
  • For the 3-year period, CureVac N.V's Receivables averaged around $11.5 million, with its median value being $9.3 million (2023).
  • Per our database at Business Quant, CureVac N.V's Receivables skyrocketed by 535.51% in 2021 and then tumbled by 98.21% in 2025.
  • CureVac N.V's Receivables (Quarterly) stood at $24.3 million in 2021, then plummeted by 62.81% to $9.0 million in 2022, then soared by 79.44% to $16.2 million in 2023, then climbed by 11.12% to $18.0 million in 2024, then crashed by 98.21% to $462,971 in 2025.
  • Its Receivables stands at $462,971 for Q2 2025, versus $4.2 million for Q1 2025 and $18.0 million for Q4 2024.